Vor Biopharma Inc.

Vor Biopharma is a company developing new treatments for autoimmune diseases, which are conditions where the immune system attacks the body's own cells. The company's main experimental drug is called telitacicept, a fusion protein designed to treat diseases including rheumatoid arthritis, lupus, myasthenia gravis, Sjögren's disease, and IgA nephropathy. Vor licensed this drug from another company and is working to test it in patients and eventually bring it to market. The company is still in the clinical development stage, meaning its drugs have not yet been approved for sale.